Medexus Pharmaceuticals (MDP) Competitors

Cipher Pharmaceuticals (TSE:CPH) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.

Do analysts rate CPH or MDP?

Cipher Pharmaceuticals presently has a consensus target price of C$12.50, indicating a potential downside of 11.97%. Medexus Pharmaceuticals has a consensus target price of C$5.58, indicating a potential upside of 30.15%. Given Medexus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Medexus Pharmaceuticals is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.67

Do institutionals and insiders believe in CPH or MDP?

1.4% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 8.3% of Medexus Pharmaceuticals shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by insiders. Comparatively, 9.1% of Medexus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has more risk & volatility, CPH or MDP?

Cipher Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Medexus Pharmaceuticals has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500.

Does the media refer more to CPH or MDP?

In the previous week, Medexus Pharmaceuticals had 9 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 9 mentions for Medexus Pharmaceuticals and 0 mentions for Cipher Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 0.89 beat Cipher Pharmaceuticals' score of 0.00 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
Medexus Pharmaceuticals	Positive

Is CPH or MDP more profitable?

Cipher Pharmaceuticals has a net margin of 102.01% compared to Medexus Pharmaceuticals' net margin of 1.00%. Cipher Pharmaceuticals' return on equity of 28.43% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	102.01%	28.43%	7.90%
Medexus Pharmaceuticals	1.00%	3.95%	4.89%

Which has preferable earnings & valuation, CPH or MDP?

Cipher Pharmaceuticals has higher earnings, but lower revenue than Medexus Pharmaceuticals. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$22.16M	16.40	C$22.60M	C$1.25	11.36
Medexus Pharmaceuticals	C$108.78M	0.97	C$1.09M	C$0.05	85.80

Does the MarketBeat Community favor CPH or MDP?

Cipher Pharmaceuticals received 174 more outperform votes than Medexus Pharmaceuticals when rated by MarketBeat users. However, 87.50% of users gave Medexus Pharmaceuticals an outperform vote while only 62.20% of users gave Cipher Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Cipher Pharmaceuticals	Outperform Votes 181 62.20%	Underperform Votes 110 37.80%
Medexus Pharmaceuticals	Outperform Votes 7 87.50%	Underperform Votes 1 12.50%

Summary

Medexus Pharmaceuticals beats Cipher Pharmaceuticals on 10 of the 18 factors compared between the two stocks.